84.75 USD
-0.48 (-0.56%)
84.6 USD
-0.15 (-0.18%)
Taking everything into account, PTGX scores 5 out of 10 in our fundamental rating. PTGX was compared to 528 industry peers in the Biotechnology industry. PTGX has an excellent financial health rating, but there are some minor concerns on its profitability. PTGX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year PTGX was profitable.
- PTGX had a positive operating cash flow in the past year.
- PTGX had negative earnings in 4 of the past 5 years.
- In the past 5 years PTGX reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of PTGX (6.54%) is better than 92.42% of its industry peers.
- The Return On Equity of PTGX (7.11%) is better than 91.10% of its industry peers.
- With an excellent Return On Invested Capital value of 2.29%, PTGX belongs to the best of the industry, outperforming 89.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROIC | 2.29% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PTGX has a better Profit Margin (21.94%) than 94.13% of its industry peers.
- PTGX has a better Operating Margin (9.09%) than 91.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- PTGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for PTGX has been increased compared to 1 year ago.
- PTGX has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 56.98 indicates that PTGX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of PTGX (56.98) is better than 96.78% of its industry peers.
- PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 56.98 |
ROIC/WACC0.26
WACC8.79%
2.3 Liquidity
- PTGX has a Current Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
- PTGX has a better Current ratio (13.05) than 88.64% of its industry peers.
- PTGX has a Quick Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of PTGX (13.05) is better than 88.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 |
3. Growth
3.1 Past
- The earnings per share for PTGX have decreased strongly by -76.69% in the last year.
- The Revenue for PTGX has decreased by -35.39% in the past year. This is quite bad
- PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
3.2 Future
- The Earnings Per Share is expected to decrease by -10.73% on average over the next years. This is quite bad
- Based on estimates for the next years, PTGX will show a quite strong growth in Revenue. The Revenue will grow by 8.27% on average per year.
EPS Next Y-146.53%
EPS Next 2Y-42.59%
EPS Next 3Y-32.08%
EPS Next 5Y-10.73%
Revenue Next Year-79.29%
Revenue Next 2Y-10.26%
Revenue Next 3Y-15.89%
Revenue Next 5Y8.27%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 136.69, which means the current valuation is very expensive for PTGX.
- 89.20% of the companies in the same industry are more expensive than PTGX, based on the Price/Earnings ratio.
- PTGX is valuated expensively when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
- The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.69 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 89.02% of the companies in the same industry are more expensive than PTGX, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 92.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 83.16 | ||
| EV/EBITDA | 208.34 |
4.3 Compensation for Growth
- A cheap valuation may be justified as PTGX's earnings are expected to decrease with -32.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.59%
EPS Next 3Y-32.08%
5. Dividend
5.1 Amount
- No dividends for PTGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
84.75
-0.48 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-19 2026-02-19/amc
Inst Owners114.02%
Inst Owner Change-0.12%
Ins Owners1.01%
Ins Owner Change2.97%
Market Cap5.30B
Revenue(TTM)209.22M
Net Income(TTM)45.91M
Analysts84.21
Price Target96.12 (13.42%)
Short Float %10.76%
Short Ratio6.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.88%
Max EPS beat(2)6.78%
EPS beat(4)4
Avg EPS beat(4)133.89%
Min EPS beat(4)4.88%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)266.75%
EPS beat(12)10
Avg EPS beat(12)179.39%
EPS beat(16)14
Avg EPS beat(16)139.25%
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)27.04%
Revenue beat(4)2
Avg Revenue beat(4)57.59%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)5
Avg Revenue beat(8)57.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.88%
PT rev (3m)34.44%
EPS NQ rev (1m)1.22%
EPS NQ rev (3m)-1.17%
EPS NY rev (1m)0.94%
EPS NY rev (3m)4.32%
Revenue NQ rev (1m)-65.91%
Revenue NQ rev (3m)32.71%
Revenue NY rev (1m)2.46%
Revenue NY rev (3m)43.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.69 | ||
| Fwd PE | N/A | ||
| P/S | 25.33 | ||
| P/FCF | 83.16 | ||
| P/OCF | 80.93 | ||
| P/B | 8.21 | ||
| P/tB | 8.21 | ||
| EV/EBITDA | 208.34 |
EPS(TTM)0.62
EY0.73%
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)1.02
FCFY1.2%
OCF(TTM)1.05
OCFY1.24%
SpS3.35
BVpS10.32
TBVpS10.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROCE | 2.89% | ||
| ROIC | 2.29% | ||
| ROICexc | 18.62% | ||
| ROICexgc | 18.62% | ||
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A | ||
| FCFM | 30.45% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 121.94% | ||
| Cap/Sales | 0.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 320.17% | ||
| Profit Quality | 138.78% | ||
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 | ||
| Altman-Z | 56.98 |
F-Score5
WACC8.79%
ROIC/WACC0.26
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
EPS Next Y-146.53%
EPS Next 2Y-42.59%
EPS Next 3Y-32.08%
EPS Next 5Y-10.73%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
Revenue Next Year-79.29%
Revenue Next 2Y-10.26%
Revenue Next 3Y-15.89%
Revenue Next 5Y8.27%
EBIT growth 1Y-87.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-196.54%
EBIT Next 3Y-33.52%
EBIT Next 5YN/A
FCF growth 1Y153.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y155.09%
OCF growth 3YN/A
OCF growth 5YN/A
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to PTGX.
What is the valuation status for PTGX stock?
ChartMill assigns a valuation rating of 3 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Overvalued.
How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 4 / 10.
What is the valuation of PROTAGONIST THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 136.69 and the Price/Book (PB) ratio is 8.21.
What is the expected EPS growth for PROTAGONIST THERAPEUTICS INC (PTGX) stock?
The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -146.53% in the next year.